)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Inhibikase Therapeutics (IKT) investor relations material
Inhibikase Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Nov, 2025
Executive summary
Advanced IKT-001, a prodrug of imatinib, toward a Phase 2b trial for pulmonary arterial hypertension (PAH) set to begin in Q4 2025; Parkinson's program discontinued and outlicensed.
Completed CorHepta Pharmaceuticals acquisition, resulting in a $7.4M non-cash R&D charge and $1.8M in stock-based compensation expense.
Raised $110M in October 2024 private placement, with potential for up to $275M upon full warrant exercise, to fund clinical development and operations.
Appointed Timothy Pigot as Chief Commercial and Strategy Officer.
Scheduled to present at the Jefferies Global Healthcare Conference in November 2025.
Financial highlights
Net loss for Q3 2025 was $11.9M ($0.13/share), compared to $5.8M ($0.65/share) in Q3 2024; nine-month net loss was $35.5M ($0.40/share), up from $15.4M ($2.03/share) year-over-year.
Research and development expenses rose 82.6% year-over-year to $7.6M for Q3 and 133.9% to $23.4M for the nine months, driven by PAH program and CorHepta acquisition costs.
Selling, general and administrative expenses increased 242.7% to $5.6M for Q3 and 197.3% to $16.8M for the nine months, including $1.0M in severance costs.
Cash, cash equivalents, and marketable securities totaled $77.3M as of September 30, 2025, down from $97.5M at December 31, 2024.
Interest income increased to $838K for Q3 and $2.7M for the nine months, reflecting higher cash balances.
Outlook and guidance
Cash runway expected to fund operations for at least the next twelve months from September 30, 2025.
Phase 2b IMPROVE-PAH trial for IKT-001 in PAH is expected to begin in Q4 2025, with interim safety review after 12 weeks for at least 50 patients.
Anticipates continued increase in R&D and operating expenses as clinical programs advance.
No revenue expected until regulatory approval and commercialization of product candidates.
Forward-looking statements highlight risks related to trial commencement and execution.
Project cash runway with Phase 2b trial costs
How does IKT-001 differentiate from imatinib?
Assess CorHepta acquisition's strategic value
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Inhibikase Therapeutics earnings date
Q4 202527 Mar, 2026
Next Inhibikase Therapeutics earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Inhibikase Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases and cancers. The company’s research primarily targets diseases related to protein misfolding, such as Parkinson's disease, by aiming to inhibit the malfunction of key cellular processes. Inhibikase Therapeutics develops therapeutics that aim to modify the progression of these diseases and improve patient outcomes. Its approach includes addressing both neurological and oncological conditions through small-molecule therapeutics. The company is headquartered in Atlanta, Georgia, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage